
Sign up to save your podcasts
Or


In this week's episode, the focus is on the latest example of no progress on reform, the mindset and intransigence it reveals, the repeated pattern, and the early evidence that it would always end this way. Can it be an opportunity? Next week's Budget is upon us, and the discussion focuses on what to look for, that just because it is not in there, does not mean it is not in there, and why gaining any cut-through will be a real challenge.
In this special episode, the focus is on the official plan to force a 'consensus' on health technology assessment reforms through a process conducted in secrecy under the guise of ethics approval. The problem with running this policy process like a clinical trial is that we do not and will not know the identities of participants, how they were selected, their input, how it is used and weighted, or even the study protocol.
Tokenistic characterisations of patient engagement are no substitute for listening and empowering. The risk of government funding for organisations and how it can impact what they do, primarily because the government is just another vested interest.
Another significant speech for the health portfolio that highlights the reform challenge and the importance of choices. A review announced in 2021 without an official response, and the reform of a major program announced with enabling legislation to be tabled next month. It's all about choices and priorities. Also, official recognition of discussions about managing a more assertive US on medicines pricing. What does it really mean?
An unhinged reaction to the new pharmacy prescribing initiative in New South Wales, why Australia needs to be humble in any health system comparison with the US, and given that the Government sets and umpires the rules for reimbursing innovative technologies, it can hardly complain when companies say no.
Australia’s health system is overly bureaucratic, opaque, and misaligned, with reforms like the HTA Review slowing access rather than improving it. Decision-making prioritises institutional processes over patients, who remain largely excluded despite bearing the consequences. The system is based on a transactional model, and without genuine patient-led change, core structural problems will continue.
In this week's episode, the discussion focuses on Health Minister Mark Butler's address at an event in Sydney and its invocation of history as the framework for pending negotiations over HTA reforms and PBS pricing. Also, strange comments by one senior official about evidence in healthcare decision-making send a clear signal about some of the thinking that might impact the next one to two years.
A powerful patient story was overshadowed by a mindset that expects patients to simplify their needs and accept delays. Some proposed reforms risk entrenching these problems, while claims of having a 'world-class system' gaslight patients and seek to shut down scrutiny. This is about power. Institutions hold it, and patients are expected to adapt, meaning they must not relent in their push for change.
How Australia’s health system is failing patients by prioritising process and cost control over timely access to treatment, forcing more to rely on compassionate access programs. HTA processes are slow, often dehumanising, and used by the government as a delay tactic. Meaningful reform requires shifting away from process-driven decision-making toward real patient needs. The opportunity articulated this week by one leader is to pursue a more strategic approach to policy. The episode also highlights the growing role of pharmacy, which is increasingly based on trust and confidence, especially post-COVID, in contrast to struggling GPs.
In this episode, we examine funding uncertainty for genomic profiling through OMICO, structural tensions within the PBS and pharmaceutical supply chain, and broader concerns about how political and financial incentives shape health policy and budget decisions. The episode concludes with an uncomfortable discussion of recent public commentary on hostility against some communities (trigger warning).
From the publisher's feed
BioPharmaDispatch - discussing the issues impacting the Australian biopharmaceutical and life sciences sectors with Paul Cross and Felicity McNeill.